Compare EPSN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EPSN | MSLE |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 186.9M |
| IPO Year | 2018 | 2007 |
| Metric | EPSN | MSLE |
|---|---|---|
| Price | $5.92 | $7.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $25.80 |
| AVG Volume (30 Days) | ★ 110.8K | 57.1K |
| Earning Date | 11-04-2026 | 11-15-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $5.44 |
| 52 Week High | $6.65 | $13.39 |
| Indicator | EPSN | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 29.04 |
| Support Level | $5.87 | $6.71 |
| Resistance Level | $5.97 | $10.58 |
| Average True Range (ATR) | 0.20 | 0.55 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 52.94 | 5.76 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.